183 related articles for article (PubMed ID: 34666344)
1. Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy.
Juluri KR; Wu QV; Voutsinas J; Hou J; Hirayama AV; Mullane E; Miles N; Maloney DG; Turtle CJ; Bar M; Gauthier J
Blood Adv; 2022 Apr; 6(7):2055-2068. PubMed ID: 34666344
[TBL] [Abstract][Full Text] [Related]
2. Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy.
Chou CK; Turtle CJ
Expert Opin Biol Ther; 2020 Jun; 20(6):653-664. PubMed ID: 32067497
[No Abstract] [Full Text] [Related]
3. Outpatient administration of CAR T-cell therapy: a focused review with recommendations for implementation in community based centers.
Perez A; Al Sagheer T; Nahas GR; Linhares YPL
Front Immunol; 2024; 15():1412002. PubMed ID: 38779668
[TBL] [Abstract][Full Text] [Related]
4. Multi-centers experience using therapeutic plasma exchange for corticosteroid/tocilizumab-refractory cytokine release syndrome following CAR-T therapy.
Pu Y; Zhao Y; Qi Y; Liu Y; Zhang M; Xiao X; Lyu H; Meng J; Zhu H; Xu K; Han W; Zhao M
Int Immunopharmacol; 2024 Mar; 130():111761. PubMed ID: 38422769
[TBL] [Abstract][Full Text] [Related]
5. Clinical Impact of Cytokine Release Syndrome on Prolonged Hematotoxicity after Chimeric Antigen Receptor T Cell Therapy: KyoTox A-Score, a Novel Prediction Model.
Nakamura N; Jo T; Arai Y; Kitawaki T; Nishikori M; Mizumoto C; Kanda J; Yamashita K; Nagao M; Takaori-Kondo A
Transplant Cell Ther; 2024 Apr; 30(4):404-414. PubMed ID: 38281589
[TBL] [Abstract][Full Text] [Related]
6. Ruxolitinib mitigates steroid-refractory CRS during CAR T therapy.
Pan J; Deng B; Ling Z; Song W; Xu J; Duan J; Wang Z; Chang AH; Feng X; Tan Y
J Cell Mol Med; 2021 Jan; 25(2):1089-1099. PubMed ID: 33314568
[TBL] [Abstract][Full Text] [Related]
7. Prolonged cytopenias after immune effector cell therapy and lymphodepletion in patients with leukemia, lymphoma and solid tumors.
Miller A; Daum R; Wang T; Wu M; Tat C; Pfeiffer T; Navai S; Heczey A; Hegde M; Ahmed N; Whittle SB; Hill L; Martinez C; Krance R; Ramos CA; Rouce RH; Lulla P; Heslop HE; Omer B; Shekar M
Cytotherapy; 2024 May; ():. PubMed ID: 38819365
[TBL] [Abstract][Full Text] [Related]
8. Acute kidney injury following treatment with CD19-specific CAR T-cell therapy in children, adolescent and young adult patients with B-cell acute lymphoblastic leukemia.
Petgrave YP; Selukar S; Epperly R; Naik S; Santos ND; Triplett BM; Gottschalk S; Bissler J; Talleur AC
Res Sq; 2023 Oct; ():. PubMed ID: 37886451
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of eltrombopag in patients with post-CAR T cytopenias.
Wesson W; Ahmed N; Rashid A; Tabak C; Logan E; Marchena-Burgos J; Nelson M; Davis JA; McGann M; Shune L; Hoffmann M; Abdallah AO; Hashmi H
Eur J Haematol; 2024 Apr; 112(4):538-546. PubMed ID: 38044594
[TBL] [Abstract][Full Text] [Related]
10. Chimeric Antigen Receptor T-Cell Therapy for Cancer and Heart: JACC Council Perspectives.
Ganatra S; Carver JR; Hayek SS; Ky B; Leja MJ; Lenihan DJ; Lenneman C; Mousavi N; Park JH; Perales MA; Ryan TD; Scherrer-Crosbie M; Steingart RM; Yang EH; Zaha V; Barac A; Liu JE
J Am Coll Cardiol; 2019 Dec; 74(25):3153-3163. PubMed ID: 31856973
[TBL] [Abstract][Full Text] [Related]
11. CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up.
Müller F; Taubmann J; Bucci L; Wilhelm A; Bergmann C; Völkl S; Aigner M; Rothe T; Minopoulou I; Tur C; Knitza J; Kharboutli S; Kretschmann S; Vasova I; Spoerl S; Reimann H; Munoz L; Gerlach RG; Schäfer S; Grieshaber-Bouyer R; Korganow AS; Farge-Bancel D; Mougiakakos D; Bozec A; Winkler T; Krönke G; Mackensen A; Schett G
N Engl J Med; 2024 Feb; 390(8):687-700. PubMed ID: 38381673
[TBL] [Abstract][Full Text] [Related]
12. Self-regulating CAR-T cells modulate cytokine release syndrome in adoptive T-cell therapy.
Lin MY; Nam E; Shih RM; Shafer A; Bouren A; Ayala Ceja M; Harris C; Khericha M; Vo KH; Kim M; Tseng CH; Chen YY
J Exp Med; 2024 Jun; 221(6):. PubMed ID: 38607370
[TBL] [Abstract][Full Text] [Related]
13. Transient acute kidney injury after chimeric antigen receptor T-cell therapy in patients with hematological malignancies.
León-Román J; Iacoboni G; Bermejo S; Carpio C; Bolufer M; García-Carro C; Sánchez-Salinas M; Alonso-Martínez C; Bestard O; Barba P; Soler MJ
Clin Kidney J; 2024 Mar; 17(3):sfae027. PubMed ID: 38500492
[TBL] [Abstract][Full Text] [Related]
14. Acute kidney injury following treatment with CD19-specific CAR T-cell therapy in children, adolescent, and young adult patients with B-cell acute lymphoblastic leukemia.
Petgrave Y; Selukar S; Epperly R; Naik S; Santos ND; Triplett BM; Gottschalk S; Bissler J; Talleur AC
Pediatr Nephrol; 2024 Mar; ():. PubMed ID: 38507119
[TBL] [Abstract][Full Text] [Related]
15. Complex association of body mass index and outcomes in patients with relapsed and refractory multiple myeloma treated with CAR-T cell immunotherapy.
Cheng H; Sun Y; Zhang X; Chen Z; Shao L; Liu J; Wang D; Chen Y; Wang X; Chen W; Sang W; Qi K; Li Z; Sun C; Shi M; Qiao J; Wu Q; Zeng L; Zheng J; Xu K; Cao J
Cytotherapy; 2024 Mar; ():. PubMed ID: 38625072
[TBL] [Abstract][Full Text] [Related]
16. Cytokine Release Syndrome Is an Independent Risk Factor Associated With Platelet Transfusion Refractoriness After CAR-T Therapy for Relapsed/Refractory Acute Lymphoblastic Leukemia.
Liu Y; Liang B; Liu Y; Wei G; Wu W; Yang L; Yang L; Huang H; Xie J; Hu Y
Front Pharmacol; 2021; 12():702152. PubMed ID: 34366854
[No Abstract] [Full Text] [Related]
17. CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS.
Sakemura RL; Manriquez Roman C; Horvei P; Siegler EL; Girsch JH; Sirpilla OL; Stewart CM; Yun K; Can I; Ogbodo EJ; Adada MM; Bezerra ED; Kankeu Fonkoua LA; Hefazi M; Ruff MW; Kimball BL; Mai LK; Huynh TN; Nevala WK; Ilieva K; Augsberger C; Patra-Kneuer M; Schanzer J; Endell J; Heitmüller C; Steidl S; Parikh SA; Ding W; Kay NE; Nowakowski GS; Kenderian SS
Blood; 2024 Jan; 143(3):258-271. PubMed ID: 37879074
[TBL] [Abstract][Full Text] [Related]
18. CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis.
Fischbach F; Richter J; Pfeffer LK; Fehse B; Berger SC; Reinhardt S; Kuhle J; Badbaran A; Rathje K; Gagelmann N; Borie D; Seibel J; Ayuk F; Friese MA; Heesen C; Kröger N
Med; 2024 Mar; ():. PubMed ID: 38554710
[TBL] [Abstract][Full Text] [Related]
19. Early induction of cytokine release syndrome by rapidly generated CAR T cells in preclinical models.
Jamali A; Ho N; Braun A; Adabi E; Thalheimer FB; Buchholz CJ
EMBO Mol Med; 2024 Apr; 16(4):784-804. PubMed ID: 38514793
[TBL] [Abstract][Full Text] [Related]
20. PrCRS: a prediction model of severe CRS in CAR-T therapy based on transfer learning.
Wei Z; Zhao C; Zhang M; Xu J; Xu N; Wu S; Xin X; Yu L; Feng W
BMC Bioinformatics; 2024 May; 25(1):197. PubMed ID: 38769505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
